UniQure Current Ratio 2013-2022 | QURE
UniQure current ratio from 2013 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| UniQure Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$0.47B |
$0.06B |
7.26 |
| 2022-06-30 |
$0.52B |
$0.05B |
10.84 |
| 2022-03-31 |
$0.58B |
$0.05B |
12.94 |
| 2021-12-31 |
$0.63B |
$0.04B |
17.09 |
| 2021-09-30 |
$0.59B |
$0.04B |
14.17 |
| 2021-06-30 |
$0.69B |
$0.05B |
15.06 |
| 2021-03-31 |
$0.28B |
$0.03B |
8.80 |
| 2020-12-31 |
$0.26B |
$0.03B |
9.47 |
| 2020-09-30 |
$0.29B |
$0.03B |
8.62 |
| 2020-06-30 |
$0.32B |
$0.03B |
10.71 |
| 2020-03-31 |
$0.35B |
$0.03B |
12.89 |
| 2019-12-31 |
$0.38B |
$0.03B |
12.15 |
| 2019-09-30 |
$0.41B |
$0.03B |
14.33 |
| 2019-06-30 |
$0.19B |
$0.02B |
8.07 |
| 2019-03-31 |
$0.21B |
$0.02B |
9.51 |
| 2018-12-31 |
$0.24B |
$0.02B |
11.85 |
| 2018-09-30 |
$0.24B |
$0.03B |
7.56 |
| 2018-06-30 |
$0.26B |
$0.03B |
8.36 |
| 2018-03-31 |
$0.15B |
$0.03B |
5.48 |
| 2017-12-31 |
$0.16B |
$0.02B |
8.47 |
| 2017-09-30 |
$0.09B |
$0.03B |
3.64 |
| 2017-06-30 |
$0.11B |
$0.02B |
4.82 |
| 2017-03-31 |
$0.12B |
$0.02B |
6.04 |
| 2016-12-31 |
$0.14B |
$0.02B |
6.34 |
| 2016-09-30 |
$0.17B |
$0.02B |
7.33 |
| 2016-06-30 |
$0.20B |
$0.03B |
7.92 |
| 2016-03-31 |
$0.21B |
$0.03B |
7.17 |
| 2015-12-31 |
$0.23B |
$0.03B |
8.48 |
| 2015-09-30 |
$0.25B |
$0.03B |
9.27 |
| 2015-06-30 |
$0.21B |
$0.03B |
8.40 |
| 2015-03-31 |
$0.05B |
$0.02B |
3.15 |
| 2014-12-31 |
$0.08B |
$0.02B |
4.68 |
| 2014-09-30 |
$0.09B |
$0.02B |
6.04 |
| 2014-06-30 |
$0.11B |
$0.02B |
6.82 |
| 2014-03-31 |
$0.11B |
$0.02B |
5.83 |
| 2013-12-31 |
$0.04B |
$0.01B |
2.65 |
| 2013-09-30 |
$0.05B |
$0.01B |
3.93 |
| 2012-12-31 |
$0.00B |
$0.01B |
0.20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.001B |
$0.524B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
